CDC’s Zika RT-PCR Test Wins Emergency Approval For Use In CLIA Labs
This article was originally published in The Gray Sheet
FDA has approved an emergency-use authorization for a molecular-based Zika virus diagnostic developed by the Centers for Disease Control and Prevention, but the test is limited to use in CDC labs and Clinical Laboratory Improvement Amendments (CLIA) labs, and comes with a long list of conditions for use.
You may also be interested in...
The US CDC-promoted Trioplex Zika virus test that won an FDA emergency-use authorization in March is nearly 40% less sensitive than a rival CDC Zika test called Singleplex, a CDC microbiologist whistleblower told superiors in April. A review of his complaints by HHS and CDC did not substantiate that, and CDC demoted him. The US Special Counsel sent a letter to the White House this week asking for further review.
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.